REVANESSE® CONTOUR™…

INFORMATION

REVANESSE® CONTOUR™ Indications for Use

REVANESSE® CONTOUR™ is an injectable dermal filler composed of cross-linked hyaluronic acid. It is indicated for the treatment of medium to deep facial wrinkles, including rhytides, and for volume restoration in areas affected by lipoatrophy or lipodystrophy. This product is also intended for soft tissue reconstruction, particularly in cases of contour deficiencies due to pathological conditions or trauma.

Key Indications:

Treatment of medium to deep facial wrinkles.
Restoration of volume loss due to lipoatrophy or lipodystrophy.
Correction of facial contour deficiencies and anatomic deformities.
REVANESSE® CONTOUR™ Dosage Information

REVANESSE® CONTOUR™ is supplied in a pre-filled, single-use syringe containing 25 mg/ml of cross-linked hyaluronic acid in a phosphate-buffered saline solution. The syringe also includes butanediol diglycidyl ether (BDDE) as the cross-linking agent. Each package contains two 1.2 ml syringes along with two sterilized 27G needles.

Dosage Summary:

Hyaluronic Acid Concentration: 25 mg/ml.
Syringe Volume: 1.2 ml per syringe.
Needle Size: 27G.
Cross-linking agent: BDDE (Butanediol diglycidyl ether).

The amount of filler used and depth of injection depend on the extent of volume loss, wrinkle depth, and facial anatomy. The effects of the treatment last an average of 6 to 12 months depending on the injection site and patient factors such as metabolism.

REVANESSE® CONTOUR™ Side Effects and Precautions

As with any injectable treatment, there are potential side effects associated with the use of REVANESSE® CONTOUR™. These side effects may range from mild injection site reactions to more severe outcomes related to injection technique or hypersensitivity reactions.

Common Side Effects:

Redness, swelling, pain, and itching at the injection site.
Tenderness or discoloration lasting up to one week.
Nodules or induration at the injection site.

Serious Side Effects:

Glabellar necrosis, abscess formation, granulomas, and hypersensitivity reactions.
Intravascular injection, which could lead to vascular occlusion, emboli, ischemia, or skin necrosis.
Allergic reactions to hyaluronic acid or BDDE cross-linker, especially in patients with multiple allergies.

Precautions:

Do not inject into areas containing other dermal fillers or implants.
Pregnant or breastfeeding women should avoid using this product.
Avoid use in patients with autoimmune disorders or those undergoing immunotherapy.
Patients with hypersensitivity to hyaluronic acid should not be treated with REVANESSE® CONTOUR™.
REVANESSE® CONTOUR™ Clinical Studies or Real-World Outcomes

REVANESSE® CONTOUR™ has shown consistent outcomes in clinical practice for the treatment of facial wrinkles and volume loss. It provides natural-looking results for patients needing moderate to deep wrinkle treatment or volume restoration.

Efficacy Results:

In clinical studies, patients experienced a significant reduction in facial wrinkles, particularly in deep lines.
The volume restoration was maintained for 6 to 12 months, with gradual biodegradation of the hyaluronic acid.
Patient satisfaction was high, particularly due to the immediate effect post-injection and the natural contouring results.

Patient Satisfaction:

The inclusion of a fine 27G needle allows for a more comfortable experience, reducing post-injection swelling.
Patients appreciated the product’s ability to restore facial balance without appearing overfilled or artificial.
REVANESSE® CONTOUR™ Drug Interactions

Certain medications and health conditions can interact with REVANESSE® CONTOUR™, increasing the likelihood of complications, especially when combined with other treatments affecting the immune system or coagulation.

Drug Interaction Warnings:

Patients taking blood thinners or NSAIDs (e.g., aspirin) should discontinue these medications 7-10 days before the procedure to reduce the risk of bruising and bleeding at the injection site.
Avoid combining this product with laser treatments, chemical peels, or dermabrasion, as there is limited data on the potential interactions.
REVANESSE® CONTOUR™ Administration & Dosage

REVANESSE® CONTOUR™ should be administered by qualified healthcare professionals with training in facial anatomy and injection techniques for dermal fillers. The injection should be performed under sterile conditions with careful consideration of injection depth and volume distribution to ensure optimal results.

Injection Guidelines:

Sterilization: The treatment area should be thoroughly disinfected before injection.
Slow injection is recommended to minimize discomfort and reduce the risk of intravascular injection.
Single-use only: Both the syringe and needle should not be reused to prevent the risk of infection.
If blanching (whitening of the skin) occurs during injection, the procedure should be stopped immediately, and the area massaged until normal color returns.
REVANESSE® CONTOUR™ Aftercare Instructions

Proper aftercare following the injection of REVANESSE® CONTOUR™ is crucial for ensuring the longevity of the results and reducing the risk of side effects.

Post-Treatment Guidelines:

Avoid touching or massaging the treated area for at least 12 hours.
Patients should refrain from exposure to extreme heat or cold, including sunlight, UV light, and extreme cold until initial swelling resolves.
Use ice packs to minimize swelling and discomfort.
Avoid intense exercise or alcohol for the first 24 hours post-injection.
Follow-Up Treatments

The results of REVANESSE® CONTOUR™ generally last between 6 and 12 months, depending on the area treated and patient factors. Follow-up treatments may be necessary to maintain the desired results.

Maintenance Recommendations:

Patients should have a follow-up appointment after 6 months to assess the results and determine if any touch-up treatments are required.
Areas with high facial movement, such as the lips, may require more frequent treatments compared to static areas like the cheekbones.